Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic in steroid-refractory non-infectious uveitis
NL-OMON23540Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of mycophenolate sodium and cyclosporine in uveitis and Posterior uveitis (non-infectious) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Therapeutic equality: decrease of inflammatory response and Therapeutic equality: improvement of BCVA. Started Sep 2007; status: active, not recruiting.
02
Drugs
mycophenolate sodiumcyclosporine
03
Conditions
uveitisPosterior uveitis (non-infectious)
Beyond the preview
Go deeper on NL-OMON23540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23540.